Acasti Pharma Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. It is developing a cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia.

1 dag sedan · Acasti Pharma Inc. (NASDAQ:ACST) trade information. Despite being -2.85% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, Apr 05 when the ACST stock price touched $0.618 or saw a rise of 12.82%.

Historical daily share price chart and data for Acasti Pharma since 2021 adjusted for splits. The latest closing stock price for Acasti Pharma as of April 06, 2021 is 0.57.. The all-time high Acasti Pharma stock closing price was 40.70 on August 05, 2013.; The Acasti Pharma 52-week high stock price is 1.22, which is 114% above the current share price. About Acasti Pharma: Acasti Pharma is a biopharmaceutical company focused on the research, development and commercialization of prescription drugs using omega-3 (OM3) fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. Co.'s primary product candidate is CaPre, an OM3 phospholipid therapeutic, which it is developing for the treatment of 2021-04-01 Today Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM 2021-03-29 Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST) today announced its operating and financial results for the third quarter of fiscal 2021 ended December 31, 2020. 2021-04-05 2021-04-05 Acasti Pharma stock is selling for under 0.55 as of the 9th of April 2021; that is 3.77 percent up since the beginning of the trading day. The stock's last reported lowest price was 0.52.

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Acasti Pharma Inc - Class A share forecasts, stock quote and buy / sell signals below.According to present data Acasti Pharma Inc - Class A's ACST shares and potentially its market environment have Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the… 2021-01-21 Technical Analysis Summary for Acasti Pharma with Moving Average, Stochastics, MACD, RSI, Stock Market Ideas. 5G Stocks Biotechnology Stocks Blockchain Stocks Bullish Moving Averages Candlestick Patterns Cannabis Stocks Dividend Stocks eMACD Buy Signals EV Stocks Gold Stocks Hot Penny Stocks Oil Stocks SPAC Stocks Top Stocks Under $10. View Acasti Pharma, Inc. ACST investment & stock information. Get the latest Acasti Pharma, Inc. ACST detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 2020-11-10 At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Back. Acasti Pharma Inc. (ACST) Add to watchlist.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Back. Acasti Pharma Inc. (ACST) Add to watchlist. NasdaqCM - NasdaqCM Real Time Price. Currency in USD. 0.5388 +0.0128 (+2.43%) At close: 4:00PM EDT.

It is developing a cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia. Historical daily share price chart and data for Acasti Pharma since 2021 adjusted for splits. The latest closing stock price for Acasti Pharma as of April 06, 2021 is 0.57..

Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM

2021-04-05 · To see how Acasti Pharma Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: ACST stock’s performance was -2.48% at last check in today’s session, and +83.33% in the past year, while Teva Pharmaceutical Industries Ltd (TEVA) has been trading +1.69% in recent session and positioned +35.54% 2020-01-29 · Acasti Pharma stock fell 64% on the news, and though shares rallied 24% the following day, the negative trend has persisted. Monday’s close was ACST’s lowest close since 2018. Acasti Pharma currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACST, but not buy more shares or sell existing shares. 2021-03-30 · Analysts gave the Acasti Pharma Inc. (ACST) stock a consensus recommendation rating of Hold, calculated at a mean rating of 2. If we narrow down to specifics, the data shows that none out of 1 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating.

2. Share. Save. 45 / 2 Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) CSO & COO Pierre Lemieux tells Proactive the Québec-based company is 'marching to the goal-line' on 1 Sep 2020 Shares of Acasti plummeted on Monday as CaPre was found to have missed its primary endpoint, which was observation of a statistically 11 Jan 2021 Thinking about buying stock in Sundial Growers, Acasti Pharma, Transenterix, Jaguar Health, or Marathon Patent Group? InvestorsObserver 9 Feb 2021 More About Acasti Pharma Inc. Acasti Pharma Inc is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 10 Feb 2021 The stock price of Acasti Pharma Inc (NASDAQ: ACST – TSX-V: ACST) is trading at over 30% pre-market as of 6:02 AM ET. This is why it Alex Ruus of Arrow Capital gives his outlook for shares of Acasti Pharma. 9 Dec 2019 Stock crashed ~60% after the phase 3 clinical trials for their leading drug CaPre, a krill oil drug used to reduce triglyceride levels in patients … 13 Jan 2020 Amarin stock popped Monday after rivals AstraZeneca and Acasti Then, tiny biotech Acasti Pharma said its rival drug known as CaPre failed Here is the latest stock price and chart of ASTEC LIFESCIENCES.
Särskild postadress företag

With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the ACST stock to lose ahead of the earnings release. Acasti Pharma has generated ($0.23) earnings per share over the last year. Acasti Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, July 5th, 2021 based off prior year's report dates. Acasti Pharma Earnings Estimates and Actuals by Quarter 2021-01-22 · Shares of Acasti Pharma spiked to a 52 week high of $1.09 during the early Thursday trading sessions.

Acasti Pharma, Inc. - Class A Common Stock ligger i en fallande trendkanal på medellång sikt. Det visar att investerare över tid har sålt till stadigt lägre kurser för 13 augusti 2019.
Restrepo documentary

kungsbacka kommunalskatt
pomodoro metoden ribbing
scholzs star
design voyage
twilfit örebro marieberg

2021-04-09 · What Makes Acasti (ACST) a New Buy Stock 08/14/20-11:00AM EST Zacks Acasti Pharma Inc. is headquartered in Laval, Canada. Full Company Report for ACST. Company Summary x. Quick Links

Acasti Pharma Stock Loses a Wall Street Supporter. The week couldn’t have gotten off to a worse start for investors of Acasti Pharma (ACST). Shares cratered by a massive 65% in Monday’s In-depth view of key statistics and finances for Acasti Pharma Inc. (ACST) on MSN Money. Acasti Pharma Inc. has a market cap of $107.82 Million and is expected to release its quarterly earnings report on February 09, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the ACST stock to lose ahead of the earnings release. Acasti Pharma currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACST, but not buy more shares or sell existing shares.